EUVIMEDEUVIMED entdecken
Systematische Übersicht

Efficacy of Adalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review

Muhammad Ilham Rakasiwi, Windy Keumala Budianti, Muhammad Ilham Dhiya Rakasiwi, Ihya Fakhrurizal Amin, Yosafat Sebastian Prayogo, Muhammad Zaki Bariz Amaanullah

Acta Medica Saliniana · 29.08.2025 · 55 (1)

DOI: 10.5457/ams.v55i1.825 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Acta Medica Saliniana, online erschienen am 29.08.2025. Verfasst von Muhammad Ilham Rakasiwi und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adalimumab (ADA) is a monoclonal antibody that is widely used as a biologic therapy for immune diseases, one of which is hidradenitis suppurativa (HS). To date, evidence-based therapeutic approaches have not been commonly used for standard of care and this is likely due to the lack of related research and the diverse therapeutic options. ADA biologic therapy shows satisfactory results and is approved by the FDA for moderate to severe HS in adult patients.

Aim

Provide an overview of the current evidence regarding the treatment of HS with ADA.

Methods

A literature search related to Hidradenitis Suppurativa Clinical Response (HiSCR) was performed on the PubMed, Scopus, and EbscoHost databases with an ADA focus on HS treatment to achieve HiSCR. Full text analysis of 8 RCT studies that met the inclusion and exclusion criteria and used a critically reviewed questionnaire from the CEBM University of Oxford.

Result

In this systematic review we obtained 8 RCTs for evaluation. The results showed that the prevalence of HiSCR after exposure to high doses of ADA, this statement was supported by 4 studies of RR>1, meaning that the addition of ADA gave patients more opportunities to achieve HiSCR. Another finding was a decrease in Sartorius scores and DLQI after ADA treatment. ADA can reduce depressive symptoms and increase pain, this statement is supported by two studies using the PHQ and PGA-SP scores.

Conclusion

ADA has good efficacy against HS, as evidenced by the high prevalence of HiSCR and quality of life of patients.

Zitieren

APA

Rakasiwi, M. I., Budianti, W. K., Rakasiwi, M. I. D., Amin, I. F., Prayogo, Y. S., & Amaanullah, M. Z. B. (2025). Efficacy of Adalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review. Acta Medica Saliniana, 55(1). https://doi.org/10.5457/ams.v55i1.825

Vancouver

Rakasiwi MI, Budianti WK, Rakasiwi MID, Amin IF, Prayogo YS, Amaanullah MZB. Efficacy of Adalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review. Acta Medica Saliniana. 2025;55(1). doi:10.5457/ams.v55i1.825

BibTeX
@article{Rakasiwi2025,
  author = {Rakasiwi, Muhammad Ilham and Budianti, Windy Keumala and Rakasiwi, Muhammad Ilham Dhiya and Amin, Ihya Fakhrurizal and Prayogo, Yosafat Sebastian and Amaanullah, Muhammad Zaki Bariz},
  title = {Efficacy of Adalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review},
  journal = {Acta Medica Saliniana},
  year = {2025},
  volume = {55},
  number = {1},
  doi = {10.5457/ams.v55i1.825}
}
Kostenlos starten →